PPA
BLCM

Parametric Portfolio Associates’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Parametric Portfolio Associates’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,254
Closed -$76K – 4014
2019
Q1 		$76K Buy
+2,254
New +$75.3K ﹤0.01% 3847
2018
Q4 		– Sell
-1,572
Closed -$97K – 3981
2018
Q3 		$97K Buy
1,572
+156
+11% +$10.6K ﹤0.01% 3850
2018
Q2 		$105K Buy
+1,416
New +$110K ﹤0.01% 3801

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parametric Portfolio Associates's BLCM Position: Q2 2019 in Review

Parametric Portfolio Associates sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 2,254 shares — an estimated $76K sold.

Parametric Portfolio Associates first reported a position in BLCM in Q2 2018 and held it in 3 quarters. The position peaked at $105K in Q2 2018. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

  • Parametric Portfolio Associates reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Parametric Portfolio Associates sold 2,254 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $76K.
  • Parametric Portfolio Associates first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Parametric Portfolio Associates's Bellicum Pharmaceuticals, Inc. position peaked at $105K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Parametric Portfolio Associates's 13F filing for Q2 2019, filed 13 Aug 2019.